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The aims of the present study were to find the frequency of the most common BRCA1 mutations in women with ovarian tumours
identified from a population-based cancer registry and in the general population, to estimate the relative risk of ovarian tumours
among the mutation carriers, and to explore the value of using CA125 as a prediagnostic test. The study was designed as a nested
case–control study within a cohort mainly consisting of participants in population-based health examinations. The data files of The
Cancer Registry of Norway and the Janus serum bank were linked to identify cases with ovarian cancer and borderline tumours.
Hereditary BRCA1 mutations were determined using archived serum samples and capillary electrophoresis. Altogether 478 ovarian
cancer patients and 190 patients with borderline tumours were identified, and 1421 and 568 matching controls were selected. Odds
ratios (OR) of developing ovarian cancer and borderline tumours in the presence of BRCA1 mutations and CA125 level were
derived from conditional logistic regression models. Among the 478 ovarian cancer patients, 19 BRCA1 mutations were identified
(1675delA, 1135insA, 816delGT and 3347delAG), none among the patients with borderline tumours. Only two of the 1989 controls
were BRCA1 mutation carriers (0.10%). The risk of ovarian cancer among the mutation carriers was strongly elevated (OR¼29, 95%
CI¼6.6–120). CA125 was a marker for ovarian cancer, but the sensitivity was low. This study showed that BRCA1 mutation carriers
have a very high risk of ovarian cancer. However, since the prevalence of BRCA1 mutations in the Norwegian population was low,
the proportion of ovarian cancers due to BRCA1 mutations seemed to be low, about 4%. The sensitivity of using CA125 only as a
screening test for ovarian cancer was low.
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Ovarian cancer is the sixth most common neoplasm among
women worldwide, and is a disease of affluent societies (Parkin,
2001). The Nordic countries, except for Finland, exhibit some of
the highest incidence rates in the world. In Norway, the incidence
of ovarian cancer has increased moderately since 1970 (Bjrge et al,
1997). Ovarian cancer patients have a poor prognosis. In Norway,
the prognosis of patients with ovarian cancer has improved
steadily since the 1950s, the 5-year relative survival reaching about
40% in 1993–1997 (Cancer Registry of Norway, 2003).
Ovarian cancer has a hereditary proportion exceeding 10% in some
populations (Risch et al, 2001; Narod and Boyd, 2002). The risk of
o v a r i a nc a n c e rc o n f e r r e db yaB R C A 1m u t a t i o nb yt h ea g eo f7 0y e a r s
is reported to be between 36 and 66% (Thompson and Easton, 2002;
Antoniou et al, 2003). Women with BRCA1 mutations are diagnosed
at a younger age than noncarriers, and most tumours in the mutation
carriers are of serous histology (Stratton et al, 1997; Risch et al, 2001).
The frequency of BRCA1 mutations in the general population has been
estimated at 0.06–0.14% (Ford et al, 1995; Whittemore et al, 1997).
In Norway, BRCA1 founder mutations are assumed to be caused
by the rapid population expansion after the Bubonic plague (Black
death) in the 14th century, which reduced the population by
approximately 60% (Drum et al, 1997). Previously, the two
founder mutations (1675delA and 1135insA) have been shown to
account for about half of all BRCA1 cases and for one-third of
hereditary breast-ovarian cancers in Norway (Borg et al, 1999). By
including 816delGT and 3347delAG, these four founder mutations
have been calculated to account for 68% of the Norwegian BRCA1
mutation carriers (Mller et al, 2001a,b). The penetrances of
1675delA and 1135insA with respect to breast and ovarian cancer
have been reported to be high (Drum et al, 1999a).
CA125 has demonstrated its value in monitoring the treatment of
patients with ovarian cancer (Makar, 1993). This marker has also in
combination with ultrasound been promising in screening for early
detection of ovarian cancer (Jacobs et al, 1999). At present, there
has been no randomised trial of screening using serial CA125 levels
and ultrasound in BRCA1 mutation carriers, and observational
cohort studies have been disappointing (Narod and Boyd, 2002).
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sIn Norway, the Janus serum bank was established in the early
1970s, and a population-based cancer registry has been in
operation since the early 1950s. In the present study, we used
these data sources to find the frequency of the most common
BRCA1 mutations in women with ovarian cancer and borderline
tumours, and in the general Norwegian population. We also aimed
at estimating the relative risk of ovarian cancer among the
mutation carriers. Further, we aimed to explore the value of using
CA125 as a prediagnostic test.
MATERIALS AND METHODS
The Janus project
The Janus serum bank was initiated in 1973, and contains
approximately 700000 serum samples, stored at  251C, from
about 330000 donors (The Norwegian Cancer Society, 2004). The
specimens have been collected from individuals who participated
in county health examinations mostly for cardiovascular diseases,
and from blood donors. The participants in the health examina-
tions were recruited from several counties in various parts of
Norway. The blood donors were from the Red Cross Blood Donor
Centre in Oslo.
The Cancer Registry of Norway
Since 1953, the Cancer Registry of Norway has received informa-
tion on all cancer patients in the population. The reporting system
is based on pathology and cytology reports, clinical records and
death certificates, and provides information about site, histological
type and stage of disease at the time of diagnosis. Also, the 11-digit
individual identification number allocated to every resident of
Norway is reported. The registration of ovarian cancers is regarded
as practically complete and of high quality (Tingulstad et al, 2002).
Through 1992, registration was based on a modified version of
ICD-7. Since 1993, ICD-O has been the basis for coding.
Identification of cases and controls
The data files of the serum bank and the cancer registry were
linked to identify cases with ovarian cancer and borderline
tumours that had donated serum at least 1 month before diagnosis.
The ovarian cancers and the borderline tumours, with correspond-
ing controls, were selected separately. If there were several serum
samples available per case, the last (youngest) sample before
diagnosis was chosen. Three women were selected from the cohort
as controls for each case. The controls were individually matched
for age at serum sampling (73 years), storage time (71 year),
county of residence and blood donor status.
Initially, 534 ovarian cancers and 215 borderline tumours were
identified. Serum samples were not available for five ovarian
cancers and three borderline tumours. Hence, 1587 and 636
matched controls were identified for the ovarian cancers and
borderline tumours, respectively. Serum samples were not avail-
able for 15 controls. Thereafter, 529 ovarian cancers and 212
borderline tumours with 1574 and 634 matching controls,
respectively, were left.
Diagnostic biopsy specimens were received from 17 pathology
laboratories for histopathologic review from 514 of the cancer
cases and 201 of the borderline cases. More than 70% of the
relevant histopathologic material already existed at the Norwegian
Radium Hospital; the remaining was sent to us as double set of
unstained slides, which were stained with haematoxylin and eosin
(HE). All specimens were re-evaluated blindly by one of the
authors (AKL). The tumours were classified and graded according
to the criteria defined by the Atlas of Tumour Pathology/AFIP
(Scully et al, 1998).
After re-evaluation of the histology diagnoses, 25 of the cancer
cases were classified as metastases and three as benign tumours,
and hence excluded from the cancer study. A total of 17 cases were
classified as borderline tumours, and hence transferred to the
borderline study. After re-evaluation of the borderline patients, 16
tumours were classified as benign, three as metastases and one as
uncertain (whether metastasis or primary tumour). All these were
excluded from the study. Of the remaining borderline cases, nine
were classified as cancers and transferred to the cancer study. After
the histological re-evaluation, 478 ovarian cancer cases and 190
borderline tumours with 1421 and 568 matching controls,
respectively, were left for analysis. The cancer cases were
diagnosed from 1975 to 2001 (median: 1994), and the borderline
tumours were diagnosed from 1974 to 2000 (median 1995). The
matching criterion on age at serum sampling was expanded for 23
controls (range: 3.5–3.9 years).
Only small differences in the median age and time between
serum sampling and diagnosis were observed between cases and
controls and between the two study populations (Table 1).
Laboratory methods
BRCA1 Mutation analysis for four founder mutations, 1675delA,
1135insA, 816delGT and 3347delAG, was carried out. Owing to
limited amount of serum, some sera were not tested for all the
founder mutations. One case and four controls were tested for one
founder mutation only, 16 cases and 30 controls were tested for
two, 91 cases and 301 controls were tested for three, while 560
cases and 1654 controls were tested for all four mutations. In this
study, persons with at least one of the four founder mutations were
termed BRCA1 mutation carriers, irrespective of the number of
mutations tested.
A detailed description of all methodological aspects is published
elsewhere (Ekstrm et al, 2004). Briefly, 5ml of serum were
aliquoted to 96-well plates (Axygen, Tamro Medlab AS, Oslo,
Norway), followed by microwave boiling at 1200W for 4min. PCR
master mix (40ml) was added to each well, mixed and subjected to
thermal cycling with primer pair specific parameters. PCR
products were analysed using an unmodified MegaBACE 1000
(AmershamBiosciences Uppsala, Sweden) capillary sequencing
instrument for fragment lengths. Samples were injected electro-
kinetically from the PCR plates, with no post-PCR cleanup, and
subjected to electrophoresis at 601C with a field strength of
145Vcm
 1 for 30min.
CA125 The serum volume available was 50ml. This was diluted
manually 10 times in assay buffer 0.05moll
 1 Tris, 0.15moll
 1
NaCl, 0.02mmoll
 1 DTPA, 0.005gl
 1 Tatrazine, 10gl
 1 Germall
II, 0.001% Triton X-100, 5gl
 1 BSA, 0.5gl
 1 bovine IgG and
15mgl
 1 MAK33, pH 7.8. MAK33, a mouse IgG1 monoclonal from
Roche, was heated to 601C for 10min (Bjerner et al, 2002). A
modified version of our fully automated in-house CA125 assays
was established as follows. In an Auto-DELFIA from Perkin-Elmer
Wallac (Turku, Finland) microtitre plates coated with streptavidin
(Perkin-Elmer Wallac) was incubated with 125ml antibody K93
(2mgml
 1 of biotinylated (Fab0)2 in assay buffer) for 20min and
the plate washed three times. Assay buffer (50ml) and diluted
serum samples (50ml) were added, incubated for 90min and the
plate washed three times. Europium-labelled antibody K101
(100ng in 100ml assay buffer) was added, incubated for 20min
and the plate washed six times before adding 200ml enhancement
solution and reading delayed fluorescence. Samples were run as
singlicates and standards and controls in duplicate. Two controls
were run twice on each microtitre plate. The low control measured
in 27 assays gave a mean of 33kUl
 1 with 5.3% CV (total error).
The high control gave mean 159 with 5.8% CV. A cutoff level of
35kUl
 1 was used as in our in-house assay. The in-house assay
has been thoroughly evaluated for interference from heterophilic
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in several workshops and the routine assay, which is essentially
similar to the modified assay except for the use of 25ml undiluted
serum as sample, behaves well as judged from international quality
control programmes (Nustad et al, 1996, 2002).
All laboratory analyses were performed with coded samples.
Statistical analyses
Odds ratios (OR) and their 95% confidence intervals (95% CI)
were derived from conditional logistic regression models.
Throughout the analysis, a significance level of 5% was used.
The data were analysed using the program package EGRET
(Statistics and Epidemiology Research Corporation (SERC Inc.),
1999). For CA125, receiver-operating characteristic (ROC) curves
were calculated, using SPSS (SPSS Inc., 2001), to evaluate the cutoff
used and the usefulness of the test. Curves were calculated for
different age groups (o50 years and X50 years) and for different
time intervals before diagnosis (o0.5, 0.5–1.4, 1.5–2.4, 2.5–4.9,
5–9 and 10 years or more).
Ethics
The Regional Ethics Committee and the National Institute of Data
Inspection approved the study.
RESULTS
BRCA1 mutations
Among the 478 ovarian cancer patients, 19 BRCA1 mutations
were identified (4.0%) (Table 1), and no mutation was discovered
among the 190 patients with borderline tumours. The frequency
of BRCA1 mutations in ovarian cancer patients younger than 50
years was 7.4% (13 of 176). Above 50 years, the frequency was
2.1% (six of 283). Two mutations (1135insA and 1675delA) were
identified among all the controls (n¼1989). One of these
controls developed ovarian cancer 3 years after being used as
a control.
The median age at diagnosis among the ovarian cancer mutation
carriers was 48 years (range: 46–54 years), 52 years (range: 33–78)
among the noncarriers. In all, 74% of the tumours among the
ovarian cancer mutation carriers were of serous histology, 52%
among the noncarriers. Seven of the ovarian cancer mutation
carriers (37%) were from the county of Rogaland in the
southwestern part of Norway (816delGT, 1675delA and 3347de-
lAG).
There was an increased risk of developing ovarian cancer among
the mutation carriers (OR¼29, 95% CI¼6.6–120) compared with
the noncarriers. Both the two mutation carriers among the controls
had two primary cancers. One had cancers of the uterine corpus
and breast, diagnosed after serum sampling. The other mutation
carrier among the controls was also included in the study as a case.
In addition to the ovarian cancer diagnosis (at the age of 48 years),
she had breast cancer. Among the other 1419 controls, 145 had at
least one cancer diagnosis. Four of the 19 ovarian cancer mutation
carriers had breast cancer as well, diagnosed prior to the ovarian
cancer.
CA125
Among the 478 ovarian cancer patients, 71 (15%) were CA125
positive at serum sampling. Of the controls, 79 (6%) were positive.
A higher risk of ovarian cancer was observed in women with
elevated CA125 (OR¼3.1, 95% CI¼2.2–4.4). Restricting the
analyses to cases with serum sampling less than 2 years prior to
diagnosis and matched controls gave a higher OR (OR¼13, 95%
CI¼4.2–37) (Table 2). Restricting the analysis to cases with serum
sampling less than 5 years prior to diagnosis also increased the OR
(OR¼4.0, 95% CI¼2.3–6.9).
Table 1 Characteristics of the study population
Ovarian cancer Borderline tumour
Cases (n¼478) Controls (n¼1421) Cases (n¼190) Controls (n¼568)
Age at diagnosis (years)
a
Median (range) 52 (33–78) 51 (30–77) 49 (26–76) 49 (23–78)
Time between serum sampling and diagnosis (years)
a
Median (range) 7.2 (0.1–26) 7.2 ( 0.5–26) 7.1 (0.1–23) 7.2 ( 0.5–23)
Histology
Serous 251 (53%) 96 (51%)
Mucinous 28 (6%) 86 (45%)
Endometrioid 76 (16%) 3 (2%)
Clear cell 53 (11%)
Mixed epithelial 24 (5%)
Undifferentiated 20 (4%)
Granulosa cell 15 (3%)
Other 11 (2%) 5 (3%)
BRCA1 mutations
816delGT 1 0 0 0
1135insA 5 1 0 0
1675delA 8 1 0 0
3347delAG 5 0 0 0
Any mutation 19 2 0 0
CA 125
Median (range) 14 (0–100) 10 (0–100) 15 (0–100) 11 (0–100)
No. positive (435Uml
 1)7 1 7 9 3 5 4 5
aFor controls, the date of diagnosis for the belonging case was used.
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CA125 levels. However, only three of these 19 women had serum
sampling less than 5 years prior to diagnosis.
A total of 35 of the patients with borderline tumours (18%) were
C A 1 2 5p o s i t i v ea ts e r u ms a m p l i n g ,4 5o ft h ec o n t r o l s( 8 % ) .Ah i g h e r
risk of borderline tumours was observed among women with elevated
CA125 (OR¼2.5, 95% CI¼1.6–4.1). Restricting the analyses to cases
with serum sampling less than 2 years prior to diagnosis and matched
controls again gave a higher OR (OR¼32, 95% CI¼4.0–260).
A higher risk of ovarian cancer was observed in CA125-positive
women older than 50 years (OR¼3.3, 95% CI¼1.5–7.1), not
among the younger women (Table 3). A higher risk of borderline
tumours was observed among CA125-positive women older than
40 years, but most pronounced in women older than 50 years
(OR¼12, 95% CI¼1.3–110).
The estimated ROC curves revealed that CA125 was a fair or
good test for ovarian cancer only with a time perspective of about
1.5 years. Therefore, we only present figures with this perspective.
For women under the age of 50 years, the area under the ROC curve
(ROC area) was 0.76 (95% CI: 0.65–0.87), indicating that CA125 is a
fair test for this perspective. For women at or above the age of 50
years, the test was good with an ROC area of 0.87 (95% CI: 0.77–
0.97). Figure 1 shows the ROC curve with time perspective of 1.5
years for all women combined. The sensitivity connected to the
chosen cutoff was 0.45, while the specificity was 0.93.
DISCUSSION
In the present seroepidemiological study, we showed that only 4%
of the ovarian cancers in Norway were due to BRCA1 mutations
(1675delA, 1135insA, 816delGT and 3347delAG), and none of the
borderline tumours. Only two of the 1989 controls were BRCA1
mutation carriers (0.10%). The risk of ovarian cancer among the
mutation carriers was, however, strongly elevated. CA125 was a
marker for ovarian cancer, but the sensitivity was low.
We have previously reported that known hereditary mutations in
the BRCA gene can efficiently be analysed in serum samples
(Ekstrm et al, 2004). With a primer design producing less than
100bp products, we were able to achieve amplification success rates
ranging from 83 to 98%, depending on primer pair. The success
rates obtained with these primers are in fact not much lower than
that observed from larger series with extracted full-length DNA
samples (data not shown). By selecting such short product sizes, it
thus appears clearly feasible to apply this technology on serum
samples that have been stored frozen for many years.
Even though the registration of ovarian cancers in Norway is
regarded as practically complete and of high quality (Tingulstad
et al, 2002), we have shown that it is important to re-evaluate the
Table 2 ORs and 95% CIs of ovarian cancer and borderline tumour according to BRCA1 mutations and CA125
Ovarian cancer Borderline tumour
Case/Ctrl OR 95% CI Case/Ctrl OR 95% CI
BRCA1
a
Negative 459/1419 1.0 Referent 190/568 1.0 Referent
Positive 19/2 29 6.6–120 0/0 — —
CA125
Negative 407/1342 1.0 Referent 155/523 1.0 Referent
Positive (overall) 71/79 3.1 2.2–4.4 35/45 2.5 1.6–4.1
Lag time (years)
b
0–1 56/167 13 4.2–37 23/69 32 4.0–260
2–3 68/201 2.1 0.8–5.5 31/92 1.9 0.7–5.6
4–5 75/224 1.5 0.6–4.2 30/90 6.0 1.5–24
6–7 77/231 2.3 0.9–5.5 27/81 1.7 0.6–4.7
8–9 72/216 1.7 0.6–4.4 20/60 0.4 0.0–3.4
10–14 99/292 3.3 1.5–7.2 47/140 1.6 0.5–4.9
15+ 31/90 13 1.4–130 12/36 1.5 0.1–17
OR¼odds ratio; CI¼confidence interval.
a816delGT, 1135insA, 1675delA and/or 3347delAG.
bFor controls, time between serum sampling and diagnosis for the belonging case.
Table 3 ORs and 95% CIs of ovarian cancer and borderline tumours
according to CA125 by age groups
Ovarian cancer Borderline tumour
OR 95% CI OR 95% CI
All
CA125 positive
Case less than 40 years old 1.1 0.3–3.5 0.8 0.2–3.0
Case 40–49 years old 3.5 2.3–5.4 2.8 1.6–4.8
Case 50+ years old 3.3 1.5–7.1 12 1.3–110
CA125 measurements less than five years prior to diagnosis
CA125 positive
Case less than 40 years old — — 4.4 0.4–51
Case 40–49 years old 4.3 2.1–8.8 6.6 2.7–16
Case 50+ years old 5.2 1.9–14 3.0 0.2–48
OR¼odds ratio; CI¼confidence interval.
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0
1-specificity
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Figure 1 Receiver operating characteristic curve for CA125 as a
prediagnostic test for ovarian cancer less than 1.5 years prior to diagnosis.
The area under the curve (ROC area) is 0.80 (95% CI: 0.72–0.88). The
points corresponding to different cut offs (kUl
 1) are marked.
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shistology in population-based studies like this. The intra- and
interobserver reproducibility of the classification of ovarian
tumours is relatively low (Stalsberg et al, 1988). The specimens
were selected from the time period 1972–2000 and from 17
different laboratories. One pathologist reviewed all histology
diagnoses to ensure important diagnostic groups. After revision
of the diagnoses, we had to omit 7% of the cases since they did not
meet the criteria for ovarian cancer or borderline tumours.
To date, relatively few studies on BRCA mutations are
population based (Risch et al, 2001; Sarantaus et al, 2001). In
most studies, women are selected on the basis of a family history
positive for cancer, or for early age at onset. In the present
population-based study, the cases were selected by linkage of the
data files of a population-based cancer registry to the files of a
serum bank where the donors mainly were participants in
population-based health examinations.
In the present study, we were not able to adjust for parity or oral
contraceptive use. However, a larger set of data is necessary to
adjust for these variables in a meaningful way.
Large differences in the BRCA1 mutation frequencies among
ovarian cancer patients have been reported. The highest frequen-
cies have been shown among Ashkenazi Jews (35 and 27%; Boyd
et al, 2000; Moslehi et al, 2000) compared to 4.7 and 3.5% in the
Finnish (Sarantaus et al, 2001) and British population (Stratton
et al, 1997), respectively. Previously, it has been reported that 3%
of Norwegian ovarian cancers are caused by BRCA1 1675delA or
1135insA (Drum et al, 1999b). We observed a low prevalence of
BRCA1 mutations in this population-based case–control study.
However, the penetrances of these mutations are among the
highest reported (Drum et al, 1999a), which were confirmed in
this study. We only tested for the four most common founder
mutations, previously being reported to account for 68% of the
BRCA1 mutation carriers in Norway (Mller et al, 2001a,b), not
for less frequent mutations. Consequently, it is likely that the true
hereditary fraction exceeds 4%. Further, BRCA2 mutations have
demonstrated to have no significant occurrence in inherited
epithelial ovarian cancer in Norway (Mller et al, 2001a).
In 1995, Ford et al (1995) stated that the frequency of BRCA1
mutation carriers in the general population was low. Based on data
from population-based studies, they estimated the frequency of
BRCA1 mutations in the British population (England and Wales)
to be 0.06%. In 1997, Whittemore et al estimated the prevalence of
BRCA1 mutations in the general US population to be 0.14%
(Whittemore et al, 1997). In the Jewish population, the frequency
of mutations in BRCA1 and BRCA2 at large is about 2% (Moslehi
et al, 2000). In the present study, only two of the 1989 (0.10%)
controls were mutation carriers.
Most ovarian carcinomas in women with BRCA1 mutations have
been reported to be of serous histology (Risch et al, 2001).
However, tumours of endometrioid and clear-cell histology are
seen occasionally (Risch et al, 2001; Narod and Boyd, 2002). In the
present study, 74% (14 of 19) of the tumours among the ovarian
cancer mutation carriers were of serous histology. One tumour was
of endometrioid histology, two were classified as mixed epithelial
tumours and two were classified as undifferentiated carcinomas.
Borderline tumours are rarely seen in women with BRCA
mutations, although a few cases have been reported (Stratton
et al, 1997; Borg et al, 1999). In the present study, no mutation
carrier was discovered among the 190 patients with borderline
tumours.
It is well documented that the mean age at diagnosis of ovarian
cancer among mutation carriers is lower than among unselected
patients, and that the prevalence of BRCA1 mutations decline with
increasing age at diagnosis (Risch et al, 2001). In the present study,
the median age at diagnosis among the mutation carriers was 49
years, 53 years among the noncarriers.
CA125, a high-molecular-weight glycoprotein, was first discov-
ered in 1981, and has since demonstrated its value in monitoring
the treatment of patients with ovarian cancer (Makar, 1993).
CA125 has also proven its value in early detection of ovarian
cancer. In 1988, Zurawski et al (1988) showed in a retrospective
seroepidemiologic study from the Janus serum bank that half of
the cases collected within the 18 months preceding diagnosis had
elevated CA125 levels (more than 30kUl
 1). Owing to the
relatively low sensitivity of this test, the combination of CA125
and ultrasound has been used for screening. However, intensive
surveillance by the use of CA125 and ultrasound has not proven to
be an effective means of diagnosing early-stage ovarian cancer in
high-risk women (Liede et al, 2002). In the present study, CA125
showed to be a marker for ovarian cancer, but with a low
sensitivity. CA125 was a fair or good test for ovarian cancer with a
time perspective of about 1.5 years only. Two of the 19 ovarian
cancer mutation carriers had elevated CA125.
In summary, this study showed that BRCA1 mutation carriers
have a very high risk of ovarian cancer. However, since the
prevalence of BRCA1 mutations in the Norwegian population was
low, the proportion of ovarian cancers due to BRCA1 mutations
seemed to be low. About 4% of the cases in the present study were
mutation carriers. The sensitivity of using CA125 only as a
screening test for ovarian cancer was low.
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